Daily treatment with STM2457 leads to impaired engraftment and prolonged survival in the MLL-AF9/Flt3-ITD mouse model or AML patient-derived xenografts (PDX) with NPM1c or MLL-AF6 PDX, suggesting that STM2457 might benefit the therapy of AML patients with MLL rearrangement or NPMc1 mutation (85). This evidence concerns the gene KMT2A and acute myeloid leukemia.